INN 108

Drug Profile

INN 108

Latest Information Update: 06 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Innovate Biopharmaceuticals
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Ulcerative colitis

Highest Development Phases

  • Phase I Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 04 Jan 2017 INN 108 is available for licensing in (excluding USA) as of 04 Jan 2017. www.innovatebiopharma.com
  • 04 Jan 2017 Early research in Ulcerative colitis (In the elderly, In children, In infants, In adolescents) in USA (PO, Liquid)
  • 28 Apr 2016 Innovate Biopharmaceuticals plans a phase II trial for Ulcerative colitis and a gastrointestinal adult orphan indication in USA (Innovate Biopharma pipeline; April 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top